Home › Research › Treatments
Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis
Wu Y, Zhu L, Chen J, Liu J, Yin K, Yang X.. Journal of neurology, 2026-10-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results Thirty-seven studies were included. Baseline microhemorrhage was associated with higher any ARIA (23.4% vs 11.5%) and ARIA-H (19.3% vs 4.2%), but not ARIA-E (5.4% vs 5.7%). ARIA incidence did not differ significantly by baseline CDR severity or deep white matter hyperintensity burden. Except for MoCA at ≤ 3 months (MD 0.515, 95% CI 0.451-0.578; 2 studies), no statistically significant changes were observed in cognitive outcomes.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wu, Y., Zhu, L., Chen, J., Liu, J., Yin, K., & Yang, X. (2026). Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis. Journal of neurology. https://doi.org/10.1007/s00415-026-14224-y
Vancouver
Wu Y, Zhu L, Chen J, Liu J, Yin K, Yang X. Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis. Journal of neurology. 2026. doi:10.1007/s00415-026-14224-y. PMID: 42907679.
BibTeX
@article{wu2026-42907679,
author = {Wu, Y. and Zhu, L. and Chen, J. and Liu, J. and Yin, K. and Yang, X.},
title = {{Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis}},
journal = {Journal of neurology},
year = {2026},
doi = {10.1007/s00415-026-14224-y},
pmid = {42907679},
url = {https://doi.org/10.1007/s00415-026-14224-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Thirty-seven studies were included.
- Baseline microhemorrhage was associated with higher any ARIA (23.4% vs 11.5%) and ARIA-H (19.3% vs 4.2%), but not ARIA-E (5.4% vs 5.7%).
- ARIA incidence did not differ significantly by baseline CDR severity or deep white matter hyperintensity burden.
- Except for MoCA at ≤ 3 months (MD 0.515, 95% CI 0.451-0.578; 2 studies), no statistically significant changes were observed in cognitive outcomes.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Effect size15.1%; 19.5%; 9.7%
- Evidence strengthHigh
How this study scored 74/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 43 of the 58 points we could judge it on, which is 74 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42907679) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 58 points we could judge it on is 74 out of 100. |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “treatment”
14 studies in the library carry the topic tag “treatment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 14 tagged studies.